UPLOAD Filing
Cocrystal Pharma, Inc.
Date: Sept. 24, 2025 · CIK: 0001412486 · Accession: 0000000000-25-010435
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290407
Letter
Re: Cocrystal Pharma, Inc. Registration Statement on Form S-1 Filed September 19, 2025 File No. 333-290407 Dear James Martin:
September 24, 2025
James Martin Co-Chief Executive Officer Cocrystal Pharma, Inc. 4400 Biscayne Boulevard Miami, FL 33137
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Michael D. Harris, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 24, 2025 James Martin Co-Chief Executive Officer Cocrystal Pharma, Inc. 4400 Biscayne Boulevard Miami, FL 33137 Re: Cocrystal Pharma, Inc. Registration Statement on Form S-1 Filed September 19, 2025 File No. 333-290407 Dear James Martin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael D. Harris, Esq. </TEXT> </DOCUMENT>